<!DOCTYPE html>

<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta content="IE=edge" http-equiv="X-UA-Compatible" />
    <meta content="width=device-width, initial-scale=1.0" name="viewport" />
    <title>Adjunctive Use of Corticosteroid Therapy (Table 16)</title>
    <meta content="GA TB Reference Guide" name="description" />
    <meta content="SitePoint" name="author" />
    <link href="../assets/uikit.css" rel="stylesheet" />
    <link href="../assets/style.css" rel="stylesheet" />
  </head>

  <body>
    <div class="uk-container">
      <div>
        <div class="chapter-header">
          <div class="header-title">
            <div>
              <img
                src="ic_chapter.svg"
                width="16"
                height="16"
                class="ic_chapter_icon"
              />
            </div>
            <p class="chapter-title">
              V. Treatment of Current (Active) Disease Therapy
            </p>
          </div>
          <p class="last-updated"><i>Last Updated October 2025</i></p>
        </div>
        <hr />
      </div>

      <p class="toggle-title" onclick="toggleItem(this)">
        Adjunct corticosteroid therapy is indicated in the treatment of
        tuberculous meningitis<span class="chevron-up">⌃</span>
      </p>
      <div class="item">
        <ul>
          <li>
            As its use along with appropriate antituberculosis drugs is
            associated with a lower mortality.
          </li>
          <li>
            For patients with tuberculous meningitis, dexamethasone or
            prednisolone is recommended as adjunct therapy for a total of 6 to 8
            weeks. An initial dose of 8 mg per day of dexamethasone for children
            < 25 kg and 12 mg per day for children > 25 kg and adults can be
            used. The initial dose is given for 3 weeks and then the dose should
            be tapered during the following 3 weeks.
          </li>
          <li>
            Adjunctive corticosteroids in treatment of pericardial tuberculosis
            did not reduce mortality, tamponade or constrictive physiology in a
            large randomized clinical trial and are thus no longer routinely
            recommended.
          </li>
          <li>
            Some experts would use corticosteroids in selected patients with TB
            pericarditis: those with large effusions and/or high levels of
            inflammation in pericardial fluid.
          </li>
        </ul>
      </div>

      <h4 id="table16" class="custom-table-title">
        Table 16. Guidelines for Treatment of Extrapulmonary Tuberculosis:
        Length of Therapy and Adjunctive Use of Corticosteroids
      </h4>
      <div class="uk-overflow-auto">
        <div class="uk-tabs-container">
          <div class="tabs">
            <button class="tab active-tab" onclick="switchTab(0, event)">
              Lymph node
            </button>
            <button class="tab" onclick="switchTab(1, event)">
              Bone (non-vertebral) and joint
            </button>
            <button class="tab" onclick="switchTab(2, event)">
              Spine without meningitis
            </button>
            <button class="tab" onclick="switchTab(3, event)">
              Spine with meningitis
            </button>
            <button class="tab" onclick="switchTab(4, event)">
              CNS tuberculosis including meningitis
            </button>
            <button class="tab" onclick="switchTab(5, event)">
              Pleural disease
            </button>
            <button class="tab" onclick="switchTab(6, event)">
              Pericarditis
            </button>
            <button class="tab" onclick="switchTab(7, event)">
              Disseminated disease
            </button>
            <button class="tab" onclick="switchTab(8, event)">
              Genitourinary
            </button>
            <button class="tab" onclick="switchTab(9, event)">
              Peritoneal
            </button>
          </div>
        </div>

        <table
          id="option-content0"
          class="uk-table tab-content option-content active-option"
        >
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td colspan="2">6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td colspan="2">Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td colspan="2">
                Pursue microbiologic proof of diagnosis prior to starting Rx
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content1" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td colspan="2">6 to 9 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td colspan="2">Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td colspan="2">Extend to 12 months if hardware is present</td>
            </tr>
          </tbody>
        </table>

        <table id="option-content2" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td colspan="2">6 to 9 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td colspan="2">
                Not recommended for TB rx but may be indicated for cord
                compression
              </td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td colspan="2">
                Most spine infection can be cured with medical Rx. Surgery
                indicated for relief of cord compression, progressive disease
                despite medical therapy, instability of the spine.
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content3" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td>9 to 12 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td>Strongly recommended</td>
            </tr>
            <tr>
              <th>Steroid Dosing for Adults</th>
              <td>
                <span class="highlight">Adults ≥ 25kg</span> <br />
                12 mg/day of <br />
                dexamethasone x 3 weeks <br />
                followed by 3-week taper
              </td>
            </tr>
            <tr>
              <th>Steroid Dosing for Children</th>
              <td>
                <span class="highlight">Children ≥ 25kg</span> <br />
                12 mg/day of <br />
                dexamethasone x 3 weeks <br />
                followed by 3-week taper <br /><br />
                <span class="highlight">Children < 25kg</span> <br />
                8 mg/day of <br />
                dexamethasone for 3 weeks <br />
                followed by 3-week taper
              </td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td>
                Most spine infection can be cured with medical Rx. Surgery
                indicated for relief of cord compression, progressive disease
                despite medical therapy, instability of the spine.
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content4" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td>9-12 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td>Strongly recommended</td>
            </tr>
            <tr>
              <th>Steroid Dosing</th>
              <td>
                A and C >= 25kg: 12 mg/day of dexamethasone x 3 weeks followed by 3-week taper<br><br>
                C < 25kg: 8 mg/day of dexamethasone for 3 weeks followed by 3-week taper
              </td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td>
                Negative CSF culture or PCR test does NOT exclude this diagnosis
                <p>Follow CSF profile for response to therapy</p>
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content5" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td>6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td>Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td>Empyema may require decortication</td>
            </tr>
          </tbody>
        </table>

        <table id="option-content6" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td>6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td>NO LONGER routinely RECOMMENDED</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td>
                Consider steroids for patients at highest risk of later
                constriction: large pericardial effusions high levels of
                inflammatory cells or markers in pericardial fluid those with
                early signs of constriction
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content7" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th colspan="1">Length of therapy</th>
              <td colspan="2">6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td colspan="2">Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td colspan="2">
                Obtain cultures from blood, urine and sputum in addition to
                clinically apparent sites of disease.
              </td>
            </tr>
          </tbody>
        </table>

        <table id="option-content8" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td colspan="2">6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td colspan="2">Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td></td>
            </tr>
          </tbody>
        </table>

        <table id="option-content9" class="uk-table tab-content option-content">
          <tbody>
            <tr>
              <th>Length of therapy</th>
              <td>6 months</td>
            </tr>
            <tr>
              <th>Corticosteroids</th>
              <td>Not recommended</td>
            </tr>
            <tr>
              <th>Additional management considerations</th>
              <td></td>
            </tr>
          </tbody>
        </table>

        <p>
          ALWAYS EVALUATE for concomitant pulmonary involvement with respiratory
          samples for smear and culture (regardless of chest imaging findings).
        </p>
        <p>Based on CID 2016:63 (1 October) • Nahid et al</p>
      </div>
    </div>
  </body>
  <script src="../assets/uikit.js" type="text/javascript"></script>
  <script src="../assets/uikit-icons.js" type="text/javascript"></script>
  <script src="main.js" type="text/javascript"></script>
</html>
